Anoro Ellipta

Anoro Ellipta

umeclidinium + vilanterol

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Per dose Umeclidinium 62.5 mcg (equiv to 74.2 mcg umeclidinium Br), vilanterol 25 mcg (as trifenatate)
Indications/Uses
Maintenance bronchodilator treatment to relieve symptoms associated w/ COPD.
Dosage/Direction for Use
Adult Recommended & max dose: 1 inhalation once daily at the same time each day.
Contraindications
Patients w/ severe milk-protein allergy.
Special Precautions
Not recommended for patients w/ asthma; relief of acute symptoms, ie, as rescue therapy for treatment of acute episodes of bronchospasm. Discontinue use if life-threatening paradoxical bronchospasm occurs. Severe CV disease. Narrow-angle glaucoma or urinary retention. Pregnancy & lactation.
Adverse Reactions
UTI, sinusitis, nasopharyngitis, pharyngitis, URTI; cough, oropharyngeal pain; constipation, dry mouth.
Drug Interactions
Effects may be weakened or antagonized w/ β-adrenergic blockers. Potential increase in systemic exposure w/ strong CYP3A4 inhibitors eg, ketoconazole.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL03 - vilanterol and umeclidinium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Anoro Ellipta inhalation powd 62.5/25 mcg
Packing/Price
(pre-dispensed) 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in